HSIC: Healthy Dental Trends And Cost Controls Are Expected To Support Balanced Outlook

Analysts have nudged their price target for Henry Schein higher, with fair value moving from about $87.21 to $88.07, as they point to healthier dental markets, recent margin improvement and a more constructive view on the stock following the latest research updates.

Analyst Commentary

Recent research around Henry Schein highlights a mix of optimism on the core dental business and cost structure, alongside some lingering caution on areas like medical growth and valuation risk.

Bullish Takeaways

Bullish analysts point to generally healthy dental markets, which they see as a support for Henry Schein's core revenue drivers and a key reason for a more constructive stance on the stock.
Recent cost reduction efforts in Q1 are cited as a positive for margins, with analysts viewing the margin expansion as evidence that management execution on efficiency initiatives is starting to show through.
Some bullish analysts view the shares as having found meaningful support after earlier weakness, which they see as improving the risk and reward trade-off relative to their fair value estimates.
The move from a neutral to a more positive rating by certain firms, alongside a US$100 price target in one instance, reflects a view that the current valuation leaves room for upside if execution on cost and dental growth continues.

Bearish Takeaways

Bearish analysts have lowered price targets at several firms, signaling concern that prior expectations may have been too optimistic relative to current fundamentals and execution risks.
There are questions around Henry Schein's medical segment, where low Q1 growth initially raised worries about competitive pressures and leaves some investors focused on whether this part of the business can support overall growth and margins.
Target cuts in recent research, including reductions of US$2, US$6, US$7 and US$10 at various firms, show that some analysts are recalibrating their view of fair value, which could limit how aggressively certain investors are willing to pay for the stock.
The mix of upgraded and lowered targets underscores that not all analysts are aligned on execution and growth visibility, which may keep a lid on valuation multiples until there is clearer evidence across both dental and medical operations.

What’s in the News for Henry Schein

Henry Schein reaffirmed earnings guidance for fiscal 2026, with total sales growth for 2026 expected to be approximately 3% to 5% over 2025. (Source: Company guidance)
Between December 28, 2025 and March 28, 2026, Henry Schein repurchased 1,609,986 shares for US$125 million, representing 1.39% of shares. (Source: Buyback tranche update)
Since the buyback was announced on December 13, 2018, Henry Schein has completed the repurchase of 43,297,237 shares, representing 32.76% of shares, for a total of US$3,095.31 million. (Source: Buyback tranche update)

Valuation Changes for Henry Schein

Fair Value: $87.21 to $88.07, a slight upward adjustment in the modeled fair value per share.
Discount Rate: 7.29% to 7.30%, a marginal increase in the rate used to discount future cash flows.
Revenue Growth: 3.76% to 3.76%, effectively unchanged in the long term growth assumption for Henry Schein's sales.
Net Profit Margin: 4.22% to 4.37%, a modest lift in expected profitability as a share of revenue.
Future P/E: 16.07x to 15.65x, a small reduction in the multiple applied to Henry Schein's projected earnings.

0 views

Key Takeaways

Focus on high-margin segments, digital transformation, and operational efficiencies is expected to boost margins and earnings growth.
Demographic shifts and industry consolidation are likely to drive sustained demand and enhance customer loyalty in key markets.
Margin pressures from competitive pricing, staffing constraints, regulatory hurdles, and execution risks could limit revenue growth and profitability despite stabilization efforts in key business areas.

Catalysts

About Henry Schein

Provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide.What are the underlying business or industry changes driving this perspective?

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments-supporting structurally higher gross margins and likely driving earnings expansion.
Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.
Henry Schein is actively pursuing operational efficiencies-including $100M+ cost savings run-rate by end of 2025 and further value creation initiatives led by KKR's Capstone-which are expected to lower operating expenses and drive net margin improvement from 2026 onward.
Continued expansion of the company's Home Solutions platform to meet increased demand for at-home healthcare, coupled with robust demographic drivers from an aging global population, are anticipated to support sustained volume growth in core distribution and specialty lines, providing a foundation for long-term revenue growth.
Dental and medical practice consolidation is increasing client reliance on integrated supply, technology, and value-added service partners like Henry Schein, enhancing share gains and customer stickiness across both the U.S. and international markets-with positive implications for top-line growth and earnings stability.

Henry Schein Earnings and Revenue Growth

Henry Schein Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Henry Schein's revenue will grow by 3.8% annually over the next 3 years.
Analysts assume that profit margins will increase from 3.0% today to 4.4% in 3 years time.
Analysts expect earnings to reach $653.3 million (and earnings per share of $5.32) by about June 2029, up from $395.0 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 15.7x on those 2029 earnings, down from 23.9x today. This future PE is lower than the current PE for the US Healthcare industry at 23.6x.
Analysts expect the number of shares outstanding to decline by 6.06% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.3%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent competitive pricing pressures, especially in key categories like gloves (where pricing remains very competitive and still below previous year levels), could continue to weigh on distribution gross margins, reducing profitability and potentially hindering earnings growth even as volume stabilizes.
Flat to modest dental patient traffic and ongoing staffing shortages (notably in hygienists and office support) are constraining underlying volume growth in the core dental business globally, which limits organic revenue expansion and exposes results to macroeconomic or reimbursement shocks in key markets.
Greater customer price sensitivity due to tariffs and the potential for large DSO/group customers to actively RFP portions of their business places greater bargaining power with customers, risking margin compression and slower top-line growth if Henry Schein cannot fully offset price concessions with its owned brands or value-added services.
International expansion, while producing some bright spots, faces country-specific regulatory challenges (e.g. recent law changes in France), currency volatility, and localized competition, all of which could restrict anticipated revenue diversification and net earnings contribution from outside the U.S.
The multi-year leadership transition and implementation of cost-saving/value creation initiatives with KKR/consulting partners carry significant execution risk; delays, integration hurdles, or cultural disruption could impair near-term efficiency gains, and if technology or AI investments lag or under-deliver, Henry Schein could lose share to more innovative or nimble competitors, pressuring long-term earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $88.07 for Henry Schein based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $100.0, and the most bearish reporting a price target of just $64.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $14.9 billion, earnings will come to $653.3 million, and it would be trading on a PE ratio of 15.7x, assuming you use a discount rate of 7.3%.
Given the current share price of $82.82, the analyst price target of $88.07 is 6.0% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Henry Schein?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook